FDA Approves Gedatolisib – Based Therapy for HR+/HER2− Advanced Breast Cancer Without PIK3CA Mutation
Jul 15, 2026
View online
FDA Approves Gedatolisib – Based Therapy for HR+/HER2− Advanced Breast Cancer Without PIK3CA Mutation
François-Clément Bidard: SERENA-6 Extended Analysis Published in Lancet Oncology
Highlights of ESMO GI 2026 in Colorectal Cancer with Davide Ciardiello
Jasmine Kamboj: Honored to Lead the Next Chapter in Community Cancer Care
Upper Tract Urothelial Carcinoma: Long-Term Results of Endoscopic Kidney-Sparing Surgery
A Landmark Day for Cancer Survivors in Ireland – All-Island Cancer Summit
Alex Singleton’s Testicular Cancer Battle: From Shock Diagnosis to Inspiring Recovery
2026 IBRI Global Forum on Science, Philanthropy, and Investment
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA
ACOG Foundation 2026 Request for Grant Proposals
HER2 and Colorectal Cancer: What Advocates Need to Know
Breast Cancer Trials 47th Annual Scientific Meeting
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
